AbbVie, Harvard partner to study coronavirus therapies

Research study efforts will occur at Harvard Medical School and center on coronaviruses and viruses that lead to hemorrhagic fever. Medical scientists will explore resistance and immunopathology, host targeting, antibodies, little particles and translational advancement.

Katie Adams –
Tuesday, August 25th, 2020
Print|Email.

” A crucial element of having a strong R&D organization is partnership with top scholastic organizations, like Harvard Medical School, to establish treatments for patients who need them most,” Michael Severino, MD, AbbVies vice chairman and president stated in the news release. “There is much to discover viral illness and the very best way to treat them. By harnessing the power of cooperation, we can establish brand-new therapeutics quicker to ensure the world is better prepared for future possible outbreaks.”.

AbbVie will offer Cambridge, Mass.-based Harvard University with $30 million to support new research study efforts concentrated on developing treatments for viral infections.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.

More articles on drug store: The 10 prescriptions most regularly filled at pharmaciesNIH to study remdesivir-esque Gilead substance as prospective COVID-19 treatmentJupiter Medical Center opens brand-new pharmacy.

In partnering with Harvard Medical School, AbbVie prepares to integrate “fundamental biology” into brand-new treatment development, according to an Aug. 25 announcement from the North Chicago, Ill.-based drugmaker..